A Multicenter Phase 1 Study of γ -secretase inhibitor RO4929097 in Combination with Capecitabine in Refractory Solid Tumors

BACKGROUND: RO4929097 is an oral inhibitor of γ -secretase that results in Notch signaling inhibition. Prior work has demonstrated that Notch signaling inhibition enhances chemotherapy sensitivity of cancer cells. This phase I study was conducted to determine maximum tolerated dose (MTD), toxicities...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Autores principales: LoConte, Noelle K., Razak, Albiruni R. A., Ivy, Percy, Tevaarwerk, Amye, Leverence, Rachael, Kolesar, Jill, Siu, Lillian, Lubner, Sam J., Mulkerin, Daniel L., Schelman, William R., Deming, Dustin A., Holen, Kyle D., Carmichael, Lakeesha, Eickhoff, Jens, Liu, Glenn
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297251/
https://ncbi.nlm.nih.gov/pubmed/25318436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0166-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares